Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASBPNASDAQ:NRXPNASDAQ:RENBNASDAQ:RPTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASBPAspire Biopharma$0.27-5.4%$0.00$0.22▼$15.80$14.09M0.913.99 million shs1.99 million shsNRXPNRx Pharmaceuticals$3.26-4.7%$2.70$1.10▼$6.01$59.13M1.54418,678 shs270,426 shsRENBRenovaro$0.29-1.3%$0.33$0.27▼$2.10$50.38M0.551.56 million shs1.79 million shsRPTXRepare Therapeutics$1.39$1.39$0.89▼$4.29$59.62M0.84247,426 shs58,069 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASBPAspire Biopharma-5.45%-4.58%-37.46%+26,899,900.00%+26,899,900.00%NRXPNRx Pharmaceuticals-4.68%+5.16%+24.43%+68.04%+33.61%RENBRenovaro-1.30%-21.54%-6.81%-42.29%-83.49%RPTXRepare Therapeutics0.00%-1.42%0.00%+36.27%-57.88%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASBPAspire BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ANRXPNRx Pharmaceuticals2.016 of 5 stars3.61.00.00.02.60.80.6RENBRenovaro1.038 of 5 stars0.02.00.00.02.23.30.6RPTXRepare Therapeutics2.6858 of 5 stars3.33.00.00.02.22.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASBPAspire Biopharma 0.00N/AN/AN/ANRXPNRx Pharmaceuticals 3.20Buy$28.50774.23% UpsideRENBRenovaro 0.00N/AN/AN/ARPTXRepare Therapeutics 2.50Moderate Buy$4.50223.74% UpsideCurrent Analyst Ratings BreakdownLatest ASBP, NRXP, RPTX, and RENB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/20/2025NRXPNRx PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.006/6/2025NRXPNRx PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.005/16/2025NRXPNRx PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.00 ➝ $31.004/30/2025NRXPNRx PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.00 ➝ $31.004/29/2025NRXPNRx PharmaceuticalsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$45.00 ➝ $46.004/2/2025NRXPNRx PharmaceuticalsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$18.00(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASBPAspire BiopharmaN/AN/AN/AN/A($2.17) per shareN/ANRXPNRx PharmaceuticalsN/AN/AN/AN/A($1.48) per shareN/ARENBRenovaroN/AN/AN/AN/A$0.89 per shareN/ARPTXRepare Therapeutics$53.48M1.11N/AN/A$3.56 per share0.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASBPAspire Biopharma-$12.54MN/A0.00∞N/AN/AN/A-508.70%N/ANRXPNRx Pharmaceuticals-$25.13M-$2.01N/AN/AN/AN/AN/A-355.00%8/13/2025 (Estimated)RENBRenovaro-$88.43M-$0.77N/A∞N/AN/A-60.38%-47.04%N/ARPTXRepare Therapeutics-$84.69M-$3.01N/AN/AN/AN/A-78.12%-67.11%N/ALatest ASBP, NRXP, RPTX, and RENB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025NRXPNRx Pharmaceuticals-$0.40-$0.34+$0.06-$0.34$1.14 million$1.14 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASBPAspire BiopharmaN/AN/AN/AN/AN/ANRXPNRx PharmaceuticalsN/AN/AN/AN/AN/ARENBRenovaroN/AN/AN/AN/AN/ARPTXRepare TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASBPAspire BiopharmaN/A0.220.22NRXPNRx PharmaceuticalsN/A0.220.22RENBRenovaroN/A0.130.13RPTXRepare TherapeuticsN/A7.427.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASBPAspire Biopharma19.17%NRXPNRx Pharmaceuticals4.27%RENBRenovaro71.41%RPTXRepare Therapeutics85.09%Insider OwnershipCompanyInsider OwnershipASBPAspire Biopharma48.00%NRXPNRx Pharmaceuticals19.00%RENBRenovaro21.72%RPTXRepare Therapeutics11.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASBPAspire BiopharmaN/A49.53 million25.75 millionN/ANRXPNRx Pharmaceuticals217.29 million14.00 millionOptionableRENBRenovaro20172.12 million134.74 millionOptionableRPTXRepare Therapeutics18042.89 million37.96 millionOptionableASBP, NRXP, RPTX, and RENB HeadlinesRecent News About These CompaniesRepare Therapeutics Inc (RPTX) Stock Forums - Investing.com5 hours ago | investing.comRepare Therapeutics Out-Licenses Discovery Platforms to DCx Biotherapeutics in Strategic DealJune 25, 2025 | insidermonkey.comRepare Therapeutics Updates Severance Benefits for ExecutivesJune 20, 2025 | tipranks.comRepare Therapeutics (NASDAQ:RPTX) Trading Down 1.3% - What's Next?June 7, 2025 | marketbeat.comRepare Therapeutics Strengthens Leadership with New Executive AppointmentJune 2, 2025 | tipranks.comRepare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial ResultsMay 13, 2025 | financialpost.comFRepare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial ResultsMay 13, 2025 | financialpost.comFRepare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial ResultsMay 13, 2025 | businesswire.comRepare Therapeutics Inc. Common Shares (RPTX)May 2, 2025 | nasdaq.comNewly Launched DCx Biotherapeutics Inks Licensing Deal With Repare TherapeuticsMay 1, 2025 | precisionmedicineonline.comPWhy Repare Therapeutics Inc.’s (RPTX) Stock Is Up 5.60%April 29, 2025 | aaii.comACathie Wood’s ARK ETF focuses on GitLab stock, sheds Repare TherapeuticsApril 15, 2025 | investing.comRepare Therapeutics CEO Lloyd Segal resigns, Steve Forte succeedsApril 1, 2025 | markets.businessinsider.comLifeSci Capital Reaffirms Their Hold Rating on Repare Therapeutics (RPTX)April 1, 2025 | markets.businessinsider.comRepare Therapeutics Names Forte as President, CEOMarch 31, 2025 | marketwatch.comRepare Therapeutics Announces Leadership TransitionsMarch 31, 2025 | businesswire.comWhat Makes Repare Therapeutics (RPTX) a New Buy StockMarch 11, 2025 | zacks.comRepare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 7, 2025 | businesswire.comRepare Therapeutics price target lowered to $5 from $10 at H.C. WainwrightMarch 7, 2025 | markets.businessinsider.comHere's Why We're Watching Repare Therapeutics' (NASDAQ:RPTX) Cash Burn SituationMarch 4, 2025 | uk.finance.yahoo.comRepare Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues LagMarch 4, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeASBP, NRXP, RPTX, and RENB Company DescriptionsAspire Biopharma NASDAQ:ASBP$0.27 -0.02 (-5.45%) As of 06/30/2025 04:00 PM EasternAspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.NRx Pharmaceuticals NASDAQ:NRXP$3.26 -0.16 (-4.68%) As of 06/30/2025 04:00 PM EasternNRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.Renovaro NASDAQ:RENB$0.29 0.00 (-1.30%) As of 06/30/2025 04:00 PM EasternRenovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.Repare Therapeutics NASDAQ:RPTX$1.39 0.00 (0.00%) As of 06/30/2025 04:00 PM EasternRepare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Alphabet’s Waymo and Services Beginning to Feel the Pressure? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
